TSHP 2014 Annual Seminar 1
|
|
- Della Lynch
- 5 years ago
- Views:
Transcription
1 MANAGING LATE STAGE ALZHEIMER S DISEASE- A PALLIATIVE APPROACH Nakia A. Beard, PharmD, CGP Assistant Professor of Pharmacy Practice, Division of Geriatrics Texas Tech University Health Sciences Center School of Pharmacy Dallas/Fort Worth April 12, 2014 DISCLOSURES The presenter has no actual or potential conflicts of interest to disclose. The presenter may discuss information regarding off-label uses for medications and their current uses in medical and pharmacy practice OBJECTIVES Upon completion of this knowledge-based activity, participants will be able to: Explain management of Alzheimer s including when to consider titration or discontinuation Discuss use of antipsychotics for management of dementia-related psychotic behaviors Given a patient case, create a therapeutic plan for a patient with dementia based on their medication list and other pertinent patient information TSHP 2014 Annual Seminar 1
2 PATIENT CASE INTRODUCTION 74 year old male PMH: Alzheimer s Dementia x 2 years Hypertension x 12 years Benign Prostatic Hypertrophy x 4 years CVA x 5 years ago Atrial fibrillation x 8 years Insomnia x 3 years Depression x 3 years Recent Information (Past month) Episodes of nausea/vomiting daily Diarrhea Only eats ~ 50% of meals Wandering in the evening Refusing medications in the evening Also states a medication was recently increased, but family cannot remember which medication ADDITIONAL PATIENT INFORMATION Patient s Medications: Lisinopril 20 mg daily Hydrochlorothiazide 25 mg daily Donepezil 10 mg daily Terazosin 4 mg daily Atorvastatin 20 mg daily Metoprolol tartrate 50 mg twice daily Warfarin 5 mg daily Multivitamins daily Tylenol PM 1 tablet daily Citalopram 20 mg daily Recent Labs / Vital Signs SCr = 1.2 mg/dl Lipid Panel = At goal AST/ALT = within normal limits INR = 2.5 BP: 138/72 mmhg Pulse: 58 bpm Weight: 64 kg Height: 5 10 WHERE DO WE BEGIN? TSHP 2014 Annual Seminar 2
3 Dementia Type TYPES OF DEMENTIAS Prevalenc e Common Signs/Symptoms Alzheimer s Dementia 50 % Gradual onset with continuing decline Social Withdrawal Paranoia Anxiety Not caused by identifiable medical, psychiatric, or neurologic condition Vascular Dementia 25% Focal neurological signs or lab evidence of cerebrovascular condition May have white-matter changes Step-wise decline in cognition Lewy Body Dementia 15% Fluctuating cognitive performance Visual hallucinations History of parkinsonism Dementia from other causes McCullough, et al. Dementia Guideline % Evidence from patient s history for a condition causing cognitive deficits Head trauma, HIV, Parkinson s, Huntington s DISEASE STAGES BY MMSE Image from: 0/tangalos.fig1.gif. Accessed September 9, 2013 GOALS OF THERAPY Disease Stage Mild Cognitive Impairment Treatment Goals Maintain function, safety, and independence Reduce or stop medication that may contribute to cognitive decline Early-Stage Dementia Maintain function and independence while preserving safety Reduce or stop medication that may contribute to cognitive decline Mid-Stage Dementia Preserve safety, function,and independence Develop skills to continue living at home and delay institutionalization Late-Stage Dementia Preserve safety, comfort, and dignity End-StageDementia Consider hospice referral McCullough, et al. Dementia Guideline 2013 TSHP 2014 Annual Seminar 3
4 WHAT DRUGS CAN WE USE? MEDICATION MANAGEMENT OF ALZHEIMER S DEMENTIA FDA Approved Agents for cognitive decline Cholinesterase Inhibitors (AChEI) Donepezil, Rivastigmine, Galantamine, Tacrine* N-methyl-d-aspartate Receptor Antagonist (NMDA) Memantine Symptomatic Treatment (Not FDA Approved for Dementia-Related Behaviors) Depression - Antidepressants Psychosis -Antipsychotics Agitation - Antipsychotics Aggression - Anticonvulsants LET S TALK ABOUT FDA APPROVED TREATMENTS TSHP 2014 Annual Seminar 4
5 DONEPEZIL (ARICEPT ) Indicated for: Mild-Severe Alzheimer s Dementia Dosage Forms: Tablets Dosing: Initial: 5 mg by mouth daily, increase to 10 mg daily (after 4-6 weeks) Maximum: 23 mg daily Adverse Effects: Gastrointestinal (3 22%) dose-dependent Insomnia (2 14%) - vivid dreams Cardiovascular: Atrioventricular block, bradycardia Administration Nighttime; Take with or without food 23 mg tablets cannot be crushed, split, or chewed Donepezil [package insert]. Feb 2012 GALANTAMINE (RAZADYNE ) Indicated for Mild-Moderate Alzheimer s Dementia Dosage Forms: Solution, Tablet, Extended Release Capsule Dosing IR: 4 mg twice daily x 4 weeks, increase to 8 mg twice daily, then 12 mg twice daily. ER: 8 mg daily x 4 weeks, increase to 16 mg daily, then 24 mg daily. Dose Adjustments Max dose is 16 mg/day if Child-Pugh Score 7-9, or CrCl < 60 ml/min Not recommended for patients with severe renal/hepatic impairment Adverse Effects: Gastrointestinal (9-25%) Cardiovascular: Atrioventricular block, Bradycardia Galantamine [package insert]. July 2013 RIVASTIGMINE (EXELON ) Indicated: Mild-Moderate Alzheimer s Dementia Mild-Moderate Dementia secondary to Parkinson s Disease Dosage Forms: Transdermal Patch Capsule Dose 4.6mg patch daily for 4 weeks, then increase to 9.5mg patch daily. Max Dose: 13.3 mg Adverse Effects: Gastrointestinal (3-12%) Cardiovascular: Arrhythmia, Bradycardia Application Site Reactions Rivastigmine [package insert]. July Rivastigmine tartrate [package insert]. July TSHP 2014 Annual Seminar 5
6 MEMANTINE (NAMENDA ) Indicated for Moderate Severe Alzheimer s Dementia Dosage Forms: Tablets, Solution, Extended-Release (ER) Capsule Dosing: Sol/Tab: 5 mg once daily, and increase in 5-mg increments (at least once weekly) to 10 mg twice daily ER Cap: 7 mg once daily, increase once weekly in 7-mg increments to 28 mg daily Dose Adjustments: If CrCl <30 ml/min, decrease IR to 5 mg BID and ER to 14 mg daily Adverse Effects: Gastrointestinal (2-5%) Neurological: CVA, TIA, Cerebral infarct Renal Acute Renal Failure Memantine [package insert]. October 2013 POSSIBLE RISKS AND BENEFITS Risks Syncope Bradycardia Respiratory Problems Initial Fecal Issues Agitation Seizure Benefits Decreased hip fracture Decreased myocardial infarction (MI) Caregiver peace of mind Delayed nursing home placement Decreased behavioral issues Gill SS, et al. Arch Intern Med Nordstrom P, et al. Eur Heart J Kroger E, et al. Am J Geriatr Pharmacother Tamimi I, et al. J Bone Miner Res WHEN TO TITRATE OR TAPER MEDICATIONS? TSHP 2014 Annual Seminar 6
7 TITRATING/TAPERING MEDICATIONS Facts to Consider Patients Changes in ADL s and cognition Cost of medications Other disease states Willingness to take medications Caregivers Caregiver Burden Time CAREGIVERS Types of Caregivers Family Home-Health Aides/Nurses Provide information Medication Compliance Home Life Desire for medication ADDITIONAL RESOURCES FOR CAREGIVERS The 36-Hour Day: A Family Guide to Caring for Persons with Alzheimer Disease, Related Dementing Illnesses, and Memory Loss in Later Life Living with Alzheimer s Website: Caring for a Patient with Dementia Website: Caregiver Resources. TSHP 2014 Annual Seminar 7
8 TITRATION VERSUS TAPERING OFF TITRATION Caregiver s ability to manage side effects Normal or elevated pulse Stable weight Ability to remain compliant TAPERING OFF Lack of effect / Inability to tolerate Refusal of medication No longer eating Hospice care Financial hardship Burns A, et al. Lancet Neurol Amuah JE, et al. Pharmacoepidemiol Drug Saf Sun Y, et al. Euro J Neurol Mansour D, et al. Am J of Geriatr Pharmacother HOW DO WE MANAGE OTHER SYMPTOMS? BEHAVIORAL DISORDERS OF COGNITIVE IMPAIRMENT Psychoses Aggression Agitation Apathy Others Hallucinations Delusions Physical Verbal Akathisia Loss of Compulsion interest s Obsessions Sleep Disorders Anxiety Depressio n Loss of self-esteem Guilty What agents do we prescribe or recommend? McCullough, et al. Dementia Guideline 2013 TSHP 2014 Annual Seminar 8
9 WHEN SHOULD ANTIPSYCHOTICS BE CONSIDERED? Pose an immediate risk of harm to self or others? Due to pain, medical condition/delirium, environmental factors, a personal need? Assess impact on caregiver and housing situation Psychoeducation and goals to maintain housing (additional consultation) Level of patient s behavioral disturbance? Severity Specific Activities Preferred Treatment Mild to Moderate Severe Wandering, flailing limbs, refusing care/medication, outbursts Physical aggression, combativeness, hitting, biting, property destruction Nonpharmacologic Approaches Psychopharmacologic Approaches McCullough, et al. Dementia Guideline 2013 TREATMENT OF BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS Drug Class/Target Symptoms Antidepressants Agitation Depression Anxiety Antidepressants Insomnia Line Medication Initial Dose Max Dose First Escitalopram 2.5 mg daily 10 mg daily First Sertraline 25 mg daily 100 mg daily Second Fluoxetine 5 mg daily 30 mg daily Third Citalopram 5 mg daily 20 mg daily First Trazodone mg daily 200 mg daily* Second Mirtazapine 7.5 mg daily 30 mg daily* McCullough, et al. Dementia Guideline 2013 TREATMENT OF BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS Drug Class/Target Symptoms Antipsychotics Delusions Hallucinations Aggression Agitation Antiepileptics Aggression Disinhibition Line Medication Initial Dose Max Dose (Total Daily Dose) First Quetiapine mg twice daily Secon d Risperidone mg daily (or twice daily) 200 mg daily 2 mg daily Third Olanzapine mg daily 10 mg daily Fourth Aripiprazole 5 mg daily 15 mg daily First Secon d McCullough, et al. Dementia Guideline 2013 Divalproex (delayed release) Carbamazepin e 125 mg daily 1,000 mg daily 100 mg daily 600 mg daily TSHP 2014 Annual Seminar 9
10 Daily DoseThresholds for Antipsychotic Medications Used to Treat BPSD Generic Name MaximumTotal Daily Dose (mg) Chlorpromazine 75 Fluphenazine 4 Haloperidol 2 Aripiprazole 10 Olanzapine 5 Quetiapine 150 Risperidone 2 CMS Memo NOW LET S GO BACK TO OUR PATIENT PATIENT CASE INTRODUCTION 74 year old male PMH: Alzheimer s Dementia x 2 years Hypertension x 12 years Benign Prostatic Hypertrophy x 4 years CVA x 5 years ago Atrial fibrillation x 8 years Insomnia x 3 years Depression x 3 years Recent Information (Past month) Episodes of nausea/vomiting daily Diarrhea Only eats ~ 50% of meals Wandering in the evening Refusing medications in the evening Also states a medication was recently increased, but family cannot remember which medication TSHP 2014 Annual Seminar 10
11 ADDITIONAL PATIENT INFORMATION Patient s Medications: Lisinopril 20 mg daily Hydrochlorothiazide 25 mg daily Donepezil 10 mg daily Terazosin 4 mg daily Atorvastatin 20 mg daily Metoprolol tartrate 50 mg twice daily Warfarin 5 mg daily Multivitamins daily Tylenol PM 1 tablet daily Citalopram 20 mg daily Recent Labs / Vital Signs SCr = 1.2 mg/dl Lipid Panel = At goal AST/ALT = within normal limits INR = 2.5 BP: 138/72 mmhg Pulse: 58 bpm Weight: 64 kg Height: 5 10 CASE QUESTIONS What are some other questions that you would like to ask this patient or the patient s caregiver? What medications are potentially inappropriate? What is the cause of the nausea, vomiting, and diarrhea? What changes in therapy would you make or recommend for this patient? Would you consider adding an antipsychotic to this patient? What if we made some changes to this patient case? IN SUMMARY Very few medications are FDA-approved for management of cognitive disorders Discussed various factors to consider when discontinuing or titrating medications for Alzheimer s dementia Identified instances when and when not to use antipsychotics for the management of Behavior and Psychological Symptoms of Dementia Identified medications that may worsen dementia Discussed some resources to help caregivers to care for patients with Alzheimer s Dementia TSHP 2014 Annual Seminar 11
12 ANY ADDITIONAL QUESTIONS? THANK YOU! If you have additional questions, please feel free to contact me at REFERENCES McCullough, et al. Dementia and Cognitive Impairment Diagnosis and Treatment Guideline. December 2012 Bareham, et al. Assessing medication appropriateness in the elderly: using Beer s and STOPP START Criteria. May 2013 Donepezil [package insert]. Pfizer Inc., New York, NY; February Galantamine [package insert]. Janssen Pharmaceuticals, Inc., Titusville, NJ; July Rivastigmine [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, NJ; July Rivastigmine tartrate [package insert]. Watson Laboratories, Inc, Corona, CA; July Memantine [package insert]. Forest Pharmaceuticals, Inc. St. Louis, MO; October Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009;169(9): Nordström P, Religa D, Wimo A, Winblad B, Eriksdotter M. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J. 2013;34(33): Kröger E, Berkers M, Carmichael PH, Souverein P, Van marum R, EgbertsT. Use of rivastigmine or galantamineand risk of adverse cardiac events: a database study from the Netherlands. Am J Geriatr Pharmacother. 2012;10(6): Tamimi I, OjeaT, Sanchez-siles JM, et al. Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: a case-control study. J Bone Miner Res. 2012;27(7): TSHP 2014 Annual Seminar 12
13 REFERENCES Alzheimer s Association. Caregiver Resources. Accessed on February 24, Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2009;8(1): Amuah JE, Hogan DB, Eliasziw M, et al. Persistence with cholinesterase inhibitor therapy in a populationbased cohort of patients with Alzheimer's disease. Pharmacoepidemiol Drug Saf. 2010;19(7): Sun Y, Lai MS, Lu CJ, Chen RC. How long can patients with mild or moderate Alzheimer's dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population-based study. Eur J Neurol. 2008;15(3): Mansour D, Wong R, Kuskowski M, Dysken M. Discontinuation of acetylcholinesteraseinhibitor treatment in the nursing home. Am J Geriatr Pharmacother. 2011;9(5): Risperidone [package insert]. Janssen Pharmaceuticals, LLC. Titusville, NJ: August 2012 Medicare atypical antipsychotic drug claims for elderly nursing home residents. HHS OIG Report May Accessed online at: Accessed February 10, Dementia in Nursing Homes: Clarification to Appendix P SOM and Appendix PP in the SOM for F309 and F329. Centers for Medicare and Medicaid Services. May 24, TSHP 2014 Annual Seminar 13
Diagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationPsychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationPsychotropic Strategies Handout Package
Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles
More informationAlzheimer Disease Agents Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Alzheimer Disease Agents Drug Class Prior Authorization Protocol This policy has been developed through review
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationAntipsychotics for Dementia Under Control or Over-Prescribed?
Antipsychotics for Dementia Under Control or Over-Prescribed? Nathaniel Hedrick, PharmD ProCare HospiceCare, Manager of Clinical Services Learning Objectives Summarize the disease progression and most
More informationDementia Pharmacotherapy
Dementia Pharmacotherapy 1 early therapeutic interventions can maximize pharmacologic efficacy with these agents 2 Selecting a Medication Not enough evidence to recommend one agent over another based on
More informationCognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics
Cognitive enhancers PINCH ME Anticholinergic burden BPSD Agitation, Aggression and antipsychotics 2 types Cholinesterase inhibitors licensed for mild to moderate AD Donepezil Galantamine Rivastigmine also
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAlzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,
2 Alzheimer s Disease Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, and functional status with no known cause or cure. Patients eventually lose cognitive, analytical,
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationPharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital
Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital with thanks to Jonathan Cavan for his input Aims Define BPSD and common symptoms
More information11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease
Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Memantine ER (Namenda XR), galantamine (Razadyne, Razadyne ER) Reference Number: CP.CPA.102 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationPharmacy Drug Class Review
April 16, 2010 Pharmacy Drug Class Review Disclaimer: Specific agents may have variations Dementia Review Focus on available treatments for Alzheimer s disease Authored By: Sarah Davis, Pharm.D Candidate
More information2/12/2016. Drugs and Dementia in the Hospice Patient. Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources
Drugs and Dementia in the Hospice Patient Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources 1 Drug Therapy: Targeted at Symptoms Cognitive: Impaired abstract thinking Impaired
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?
ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be
More informationMedications for treating people with dementia: summary of evidence on cost-effectiveness
Medications for treating people with dementia: summary of evidence on cost-effectiveness Martin Knapp, A-La Park and Alistair Burns PSSRU, London School of Economics and Political Science v4 23 July 2017
More informationCauses of Transient Incontinence. Geriatrics: Urinary Incontinence, Dementia, and Delirium. Classification of Established Incontinence
Causes of Transient Geriatrics: Urinary, Dementia, and Delirium Carla Zeilmann, PharmD, BCPS St. Louis College of Pharmacy Therapeutics 3 Fall 2003 D delirium I infection A atrophic urethritis and vaginitis
More informationDEMENTIA AND MEDICATION
DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,
More informationDebra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
More informationDiscontinuing Dementia Medications Case April Patient Case
Discontinuing Dementia Medications Case April 2017 Patient Case MJ is an 86 year-old female with a primary diagnosis of Alzheimer s disease and history of anemia, cystitis, depression, Type II DM, HTN,
More informationBEHAVIORAL PROBLEMS IN DEMENTIA
BEHAVIORAL PROBLEMS IN DEMENTIA CLINICAL FEATURES Particularly as dementia progresses, psychiatric symptoms may develop that resemble discrete mental disorders such as depression or mania The course and
More informationEARLY DEMENTIA. University of Hawaii Geriatric Medicine Department
EARLY DEMENTIA University of Hawaii Geriatric Medicine Department INTRODUCTION Dementia is very prevalent Screening and early diagnosis is important Evaluation Dementia Management DEMENTIA IS VERY PREVALENT
More informationRational Medication Use in Dementia
Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this
More informationAlzheimer dementia: Starting, stopping drug therapy
REVIEW LUKE D. KIM, MD, FACP, CMD Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Center for Geriatric Medicine, Medicine
More informationOptimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches
Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize
More informationManagement of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
More informationOrganization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit
Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Problem: For dementia patients, antipsychotic medications are prescribed
More informationPharmacological Treatment of Aggression in the Elderly
Pharmacological Treatment of Aggression in the Elderly Howard Fenn, MD Adjunct Clinical Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University Self-Assessment Question
More informationThe Basics of Alzheimer s Disease
2017 Memory Loss Conference The Basics of Alzheimer s Disease Tom Ala, MD Center for Alzheimer s Disease and Related Disorders Southern Illinois University School of Medicine Springfield, Illinois SIU
More informationDrugs used to relieve behavioural and psychological symptoms in dementia
alzheimers.org.uk Drugs used to relieve behavioural and psychological symptoms in dementia People with dementia may develop behavioural and psychological symptoms including restlessness, aggression, delusions,
More informationManagement of Behavioral Problems in Dementia
Management of Behavioral Problems in Dementia Ghulam M. Surti, MD Clinical Assistant Professor Department of Psychiatry and Human Behavior Warren Alpert Medical School of Brown University Definition of
More informationOutlines! Current Issue in Management. of Dementia! Cholinesterase Inhibitors! Medications that soon to be used in. Papan Thaipisuttikul, M.D.
Current Issue in Management of Dementia! Papan Thaipisuttikul, M.D. Department of Psychiatry Ramathibodi Hospital! Outlines! Current medications use in dementia management in Thailand. Medications that
More informationGALANTAMINE. THERAPEUTICS Brands Razadyne Razadyne ER see index for additional brand names
GALANTAMINE THERAPEUTICS Brands Razadyne Razadyne ER see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: acetylcholine multi-modal; enzyme inhibitor; receptor PAM (ACh-MM)
More informationMental Health Subcommittee of PTAC meeting held 21 June (minutes for web publishing)
Mental Health Subcommittee of PTAC meeting held 21 June 2010 (minutes for web publishing) Mental Health Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationPsychotropic Medication. Including Role of Gradual Dose Reductions
Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which
More informationNeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M.
ISSNISSN ISSN: 2456-3927 NeuroPharmac Journal Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. Alshahrani www. neuropharmac.com Jan-April 2018, Volume 3, Issue
More informationBehavioral and Psychological Symptoms of dementia (BPSD)
Behavioral and Psychological Symptoms of dementia (BPSD) Chris Collins - Old Age Psychiatrist, Christchurch chris.collins@cdhb.health.nz Approaching BPSD: the right mindset Assessment Non-drug management
More informationBEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
More informationUSING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE?
USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? Mugdha Thakur, MD Associate Professor of Psychiatry and Behavioral Sciences Duke University
More informationMichael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center
Michael A. Lobatz MD The Neurology Center Scripps Rehabilitation Center Dementia an acquired syndrome consisting of a decline in memory and other cognitive functions Alzheimer s Disease Fronto temporal
More informationCognitive disorders. Dr S. Mashaphu Department of Psychiatry
Cognitive disorders Dr S. Mashaphu Department of Psychiatry Delirium Syndrome characterised by: Disturbance of consciousness Impaired attention Change in cognition Develops over hours-days Fluctuates during
More informationWHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together. Presented by
WHEN THE GOING GETS TOUGH: Working Through the Challenges of Dementia Together Presented by Our agenda for today Understanding behavioral symptoms in people living with dementia Briefly review key strategies
More informationInterface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE
Cholinesterase inhibitors and Memantine are now classified as green (following specialist initiation) drugs by the Greater Manchester Medicines Management Group. Who will diagnose and decide who is suitable
More informationPrimary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia
Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia This prescribing guideline provides the necessary information and guidance to support clinicians in the
More informationGERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017
More informationPharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018
Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More informationPresented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD
Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Define BPSD and review the spectrum of associated symptoms Review pharmacologic and non-pharmacologic treatments for BPSD Evaluate
More informationMedication Treatments for Dementia. Stephen Thielke
Medication Treatments for Dementia Stephen Thielke Treatment is a MORAL decision. Facts can help you determine HOW to accomplish something. Facts cannot tell you WHAT YOU WANT to accomplish. Dementia Meds
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More information9/11/2012. Clare I. Hays, MD, CMD
Clare I. Hays, MD, CMD Review regulatory background for current CMS emphasis on antipsychotics Understand the risks and (limited) benefits of antipsychotic medications Review non-pharmacologic management
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationObjectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition
Reducing the Use of Antipsychotics in Long Term Care Communities Alan W. Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy Objectives Recognize the clinical evidence for the need to change
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationTechnology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 NICE 2017. All rights reserved.
More informationScreening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia
Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Measure Description Percentage of patients with dementia for whom there was a documented screening* for behavioral
More informationMEDICATIONS IN MANAGING DIFFICULT BEHAVIORS
MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS A REALITY CHECK reality check Noun informal an occasion on which one is reminded of the state of things in the real world. ROBERT LACOSTE, MD MEDICAL DIRECTOR,
More informationDementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE
Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Objectives At the conclusion of the session, participants will be
More informationDelirium. Assessment and Management
Delirium Assessment and Management Goals and Objectives Participants will: 1. be able to recognize and diagnose the syndrome of delirium. 2. understand the causes of delirium. 3. become knowledgeable about
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal
More informationRecognition and Management of Behavioral Disturbances in Dementia
Recognition and Management of Behavioral Disturbances in Dementia Danielle Hansen, DO, MS (Med Ed), MHSA INTRODUCTION 80% 90% of patients with dementia develop at least one behavioral disturbances or psychotic
More informationIf a bad thing is happening to a patient, a drug did it until proven otherwise
Dr Vicki s First Rule of Geriatrics Deprescribing in the Elderly Victoria Braund MD, FACP, CMD Director, Division of Geriatrics NorthShore University HealthSystem Medical Director, Brandel Health & Rehab
More informationCOMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK
COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics
More informationCurrent Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London
Current Treatments for Dementia and Future Prospects James Warner St Charles Hospital, London Dementia Cognitive Non-cognitive (BPSD) Memory orientation language other cognitive abilities praxis planning
More informationAppendix N: Research recommendations
Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist
More informationPiecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder
Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives
More informationEvidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia
Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia ADI 2018, Chicago FACULTY OF MEDICINE Dr Emily Reeve NHMRC Cognitive Decline
More information-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine
-Guidelines for the discontinuation of oral antipsychotics in patients with BPSD within the primary care setting Summary- Quetiapine An independent report Time for action 1 by Professor Sube Banerjee looked
More informationThe Psychopharmacology of Alzheimer s Disease. Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school
The Psychopharmacology of Alzheimer s Disease Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school Overview of Alzheimer s Disease Alzheimer s is a progressive degenerative disease Prevalence
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationMedications for Alzheimer s disease: are they right for you?
Medications for Alzheimer s disease: are they right for you? There are no medications today that can cure Alzheimer s disease. But there are currently four medications approved by Health Canada which can
More informationPharmacotherapy of Dementia Behaviors
This Clinical Resource gives subscribers additional insight related to the Recommendations published in June 2017 ~ Resource #330601 Pharmacotherapy of Dementia Behaviors (Also see our chart specific to
More informationUse of Psychotropic Medications in Older Adults with Dementia!
Use of Psychotropic Medications in Older Adults with Dementia! Deepa Pattani, PharmD, RPh Owner: PrevInteract Health Deepa.Pattani@PrevInteract.com 972-372-9775 About Me Deepa Pattani, PharmD, RPh with
More informationPrescribing Framework for Rivastigmine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationEssential Shared Care Agreement Drugs for Dementia
E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient
More informationClinical Policy: Rivastigmine (Exelon) Reference Number: CP.PMN.101 Effective Date: Last Review Date: 02.18
Clinical Policy: (Exelon) Reference Number: CP.PMN.101 Effective Date: 03.01.17 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationDementia of the Alzheimer Type: the Drug Treatment Debate
Dementia of the Alzheimer Type: the Drug Treatment Debate I have no financial conflict of interest. Many years ago I was given a trip to San Fran and taught to use a slide set from the drug company. I
More informationDrugs that poison the elderly
Drugs that poison the elderly Brent Tipping Sub-specialist Geriatrician and Specialist Physician Division of Geriatric Medicine, Department of Medicine University of the Witwatersrand To treat or not to
More informationDementia Care Pathway
Document level: West Locality Code: CC41 Issue number: 1 Dementia Care Pathway Lead executive Authors details Type of document Target audience Document purpose Medical Director Dr Anushta Sivananthan Dr
More informationScreening Summary (SS2)
15Screening SummarySS217 Aug 06 Depression in Alzheimer s Disease Study - 2 DIADS-2 Screening Summary (SS2) Keyed: ( ) Purpose: Document findings about eligibility for DIADS-2 and about medical and social
More informationDosing and Switching Strategies for Long-Acting Risperidone
Clinical Guidelines: Dosing Long-Acting Risperidone Clinical Guidelines Dosing and Switching Strategies for Long-Acting Risperidone Stephen R. Marder, M.D.; Robert Conley, M.D.; Larry Ereshefsky, Pharm.D.,
More informationAlthough cholinesterase inhibitors (ChEIs) and memantine
High-dose donepezil or memantine: Next step for Alzheimer s disease? Larger dosages may benefit patients who have maxed out existing therapies Indrapal Singh, MD Assistant Professor Department of Geriatric
More informationAppendix D: Included Studies adverse effects review
DELIRIUM APPENDICES (Draft for Consultation) Appendix D: Included Studies adverse effects review Table D1: Studies directly comparing two antipsychotic agents in delirium Author Study design Setting Age
More information1. Developed April Revised May 2017; November 2015; March 2014; March 2012.
Texas Vendor Drug Program Drug Use Criteria: Memantine (Namenda ) Publication History 1. Developed April 2010. 2. Revised May 2017; November 2015; March 2014; March 2012. Notes: Information on indications
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 EXELON 13.3 mg/24 hours, transdermal patch B/30 sachets (CIP: 34009 268 908 1 0) Applicant: NOVARTIS
More informationClinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease
Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top
More informationThe most common cause of dementia in the elderly is. Cholinesterase Inhibitors in the Treatment of Dementia REVIEW ARTICLE. Jay M.
Cholinesterase Inhibitors in the Treatment of Dementia Jay M. Ellis, DO Dementia associated with probable Alzheimer s disease (AD) is one of the most common types of dementia. Patients with AD often have
More informationNuplazid. (pimavanserin) New Product Slideshow
Nuplazid (pimavanserin) New Product Slideshow Introduction Brand name: Nuplazid Generic name: Pimavanserin Pharmacological class: Atypical antipsychotic Strength and Formulation: 17mg; tablets Manufacturer:
More informationUnderstanding Dementia
Dementia Handbook for Carers Essex Understanding Dementia What is dementia? 1 Summary of dementia symptoms 4 Medication and treatment 5 1 Dementia is the name for several conditions that lead to the progressive
More informationSYNOPSIS. Trial No.: RIS-USA-70 Clinical phase: III. JRF, Clinical Research Report RIS-USA-70, 16 October, 1998 N Trial period: Start: 20 Nov 95
SYNOPSIS Trial identification and protocol summary Company: Janssen Research Foundation Finished product: RISPERDAL Active ingredient: Risperidone (R064,766) Title: An open-label, long-term study of risperidone
More informationA BRIEF LOOK AT DEMENTIA
Dementia A BRIEF LOOK AT DEMENTIA David Kaufman, MD Neurology Consultants of Bellin Health November 2, 2017 Defined as a progressive decline in cognitive function that impairs daily activities. Always
More information